Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19.
A Monoclonal antibody
Target Spike protein of SARS-CoV-2
Routes of administration Intravenous
Pemivibart is authorized for the pre-exposure prophylaxis (prevention) of COVID‑19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms (88 lb).
It is authorized for individuals who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to an individual infected with SARS‑CoV‑2; and who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID‑19 vaccination.
It is administered as a single intervenous infusion, which can be administered every three months if needed. Adverse effects are rare include fatigue, nausea, headaches, and anaphylaxis.